Table 3 Granulomatous organ involvement
From: Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Number of patient (%) | |
|---|---|
Organ involvement | |
Lung | 30 (91) |
Skin | 15 (45) |
Lupus pernio | 8 |
Other skin manifestation | 7 |
Upper airway | 9 (27) |
Eye | 7 (21) |
Liver | 4 (12) |
CNS | 6 (18) |
Cardiac | 3 (9) |
GI | 1 (3) |
Spleen | 3 (9) |
Peripheral lymph node | 2 (6) |
Bone marrow | 1 (3) |
Muscle | 1 (3) |
Arthritis | 1 (3) |
Organ involvement | |
1 | 12 (36) |
2 | 7 (21) |
≥ 3 | 14 (43) |
Multiorgan (≥ 2) | 21 (64) |
Organ/manifestation for which infliximab was initiated | |
Lungs | 14 (33) |
Skin | 12 (28) |
Upper airway | 7 (16) |
CNS | 6 (14) |
Peripheral lymph node | 1 (2) |
GI | 1 (2) |
Uveitis | 1 (2) |
Arthritis | 1 (2) |
Concomitant therapy | |
Corticosteroid alone | 5 (15) |
Second line immunosuppressive alone | 9 (27) |
Corticosteroid + second line immunosuppressive | 19 (58) |